Shares of Aehr Test Systems surged 6.1% in pre-market to $72.00, snapping a brutal slide from a recent high near $84 as investors circled back to the company's blockbuster order book ahead of its fiscal year-end earnings report on July 14. The rebound spotlights a fundamental tension: Aehr is booking orders at a historic pace for AI chip-testing equipment, but its current revenue base is a fraction of its market cap.
A Single $41 Million Order Changed the Conversation. In April, Aehr landed a $41 million production order from its lead hyperscale customer for testing custom AI processor chips — the largest order in company history.
That deal pushed second-half FY26 bookings past $92 million , blowing past the prior guidance range of $60–$80 million. For a company that posted just $10.3 million in Q3 revenue, a 44% year-over-year decline , the sheer size of incoming orders has become the bull case in a single number.
Revenue Today Doesn't Match the Hype. Over the trailing twelve months, Aehr generated only $45.3 million in revenue against a market cap of roughly $2.94 billion.
The stock trades at approximately 35 times FY2027 revenue estimates — a level one Seeking Alpha analyst called "priced to perfection." Gross margins compressed to 36.5% from 42.7% a year earlier , and the company is still posting net losses. The bet is that the massive backlog converts to profitable shipments starting in FY27; if it doesn't, the valuation has little cushion.
The Backlog Is Real, But So Is the Execution Risk. Aehr exited Q3 with a reported backlog of $38.7 million, which swelled to a record $50.9 million after early Q4 bookings of $12.2 million.
Management expects a return to non-GAAP profitability in Q4 and sees its strong backlog positioning the company for significant revenue growth in FY27. But 13% of outstanding shares are sold short , signaling meaningful skepticism. Only an estimated 5–20% of custom AI chips currently use burn-in testing , which suggests the addressable market could expand — or that adoption could disappoint.
Earnings Next Week Will Be the Verdict. Aehr reports its full fiscal 2026 results on July 14. That report will reveal whether the order surge translated into real Q4 revenue acceleration. Until then, today's bounce is a vote of confidence in the backlog — not proof the growth story has arrived.